Zongertinib, an oral HER2-selective tyrosine kinase inhibitor, achieved a 71% objective response rate in previously treated HER2-mutant NSCLC patients with tyrosine kinase domain mutations.
Median duration of response was 14.1 months, and median progression-free survival was 12.4 months in the primary cohort.
The safety profile was manageable, with mostly low-grade adverse events and no drug-related interstitial lung disease observed.
Zongertinib demonstrated activity even in patients previously treated with HER2-directed antibody–drug conjugates and those with non–tyrosine kinase domain mutations.
Clinical Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.